Depomed To Make Treasure Out of J&J Trash With Nucynta Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
Depomed is leveraging all its value to bet on a drug that was virtually ignored by its big pharma owner with its billion-dollar buy of Janssen’s Nucynta.